Leung Ching-Hsiang, Wang Nai-Yu, Liu Chang-Pan, Weng Li-Chuan, Hsieh Feng-Chih, Lee Chun-Ming
Division of Endocrinology and Metabolism, Department of Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
J Microbiol Immunol Infect. 2008 Dec;41(6):491-8.
The emergence of multidrug-resistant (MDR) Pseudomonas aeruginosa is a challenging clinical problem. This study investigated the source of an outbreak of MDR P. aeruginosa infections and the role of combination therapy in its management.
MDR P. aeruginosa isolates were collected at the MacKay Memorial Hospital, Taipei, Taiwan, and antibiotic synergy was investigated based on antibiotic susceptibility tests using a combination of antibiotics. Isolates of patients with MDR P. aeruginosa bacteremia were selected for genetic analysis by pulsed-field gel electrophoresis.
A combination of ceftazidime, amikacin, and sulbactam had significant synergistic effects against bloodstream MDR P. aeruginosa isolates and was more beneficial clinically compared with other antibiotic combinations. The major source of MDR P. aeruginosa infection was located and stringent infection control measures were enforced.
The results of this study suggest that use of triple antimicrobial therapy (ceftazidime, amikacin, and sulbactam) can be a useful alternative treatment for MDR P. aeruginosa infection in certain circumstances.
多重耐药铜绿假单胞菌的出现是一个具有挑战性的临床问题。本研究调查了多重耐药铜绿假单胞菌感染暴发的源头以及联合治疗在其管理中的作用。
在台湾台北市的麦凯纪念医院收集多重耐药铜绿假单胞菌分离株,并基于抗生素敏感性试验,采用联合抗生素的方法研究抗生素协同作用。选择多重耐药铜绿假单胞菌菌血症患者的分离株进行脉冲场凝胶电泳基因分析。
头孢他啶、阿米卡星和舒巴坦联合使用对血流多重耐药铜绿假单胞菌分离株具有显著的协同作用,与其他抗生素联合使用相比,在临床上更有益。确定了多重耐药铜绿假单胞菌感染的主要源头,并实施了严格的感染控制措施。
本研究结果表明,在某些情况下,使用三联抗菌疗法(头孢他啶、阿米卡星和舒巴坦)可能是治疗多重耐药铜绿假单胞菌感染的一种有效替代疗法。